Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2022

May 17, 2022

SELL
$11.56 - $19.76 $552,568 - $944,528
-47,800 Reduced 17.66%
222,900 $3.62 Million
Q4 2021

Feb 15, 2022

SELL
$11.18 - $15.46 $1.46 Million - $2.02 Million
-130,900 Reduced 32.59%
270,700 $3.75 Million
Q3 2021

Nov 16, 2021

SELL
$14.21 - $17.65 $626,661 - $778,364
-44,100 Reduced 9.89%
401,600 $5.77 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $1.19 Million - $2.16 Million
125,100 Added 39.02%
445,700 $7.05 Million
Q1 2021

May 18, 2021

BUY
$7.37 - $13.61 $1.7 Million - $3.13 Million
230,200 Added 254.65%
320,600 $3.26 Million
Q4 2020

Feb 17, 2021

BUY
$3.37 - $8.61 $84,924 - $216,972
25,200 Added 38.65%
90,400 $673,000
Q3 2020

Nov 17, 2020

BUY
$3.43 - $5.53 $223,636 - $360,556
65,200 New
65,200 $224,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.47B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.